Baidu
map

Int J Audiol:听力损失与β-受体阻滞药的使用有关

2017-12-06 AlexYang MedSci原创

最近,有研究人员调查验证了这样的一个假设,即使用β-受体阻滞药的病人将会发展患有听力损失。研究人员设计的研究是一个代表性的研究。研究群体总共包括了125名病人,并参与完成了研究。其中的63名病人为β-受体阻滞药使用者,62名为非β-受体阻滞药使用者。研究发现,卡维地洛与听力损失显著相关。其他β-受体阻滞药物包括美托洛尔和阿替洛尔则与听力损失并不存在相关联系。研究人员进行了线性多回归分析,并且包括了

最近,有研究人员调查验证了这样的一个假设,即使用β-受体阻滞药的病人将会发展患有听力损失。研究人员设计的研究是一个代表性的研究。研究群体总共包括了125名病人,并参与完成了研究。其中的63名病人为β-受体阻滞药使用者,62名为非β-受体阻滞药使用者。

研究发现,卡维地洛与听力损失显著相关。其他β-受体阻滞药物包括美托洛尔和阿替洛尔则与听力损失并不存在相关联系。研究人员进行了线性多回归分析,并且包括了性别、年龄、缺血性心脏病、心力衰竭/扩张型心肌病等变量,速尿灵和卡维地洛的使用作为所有频率时总听力损失严重度预测因子。另外,研究人员发现,年龄和性别以及卡维地洛是听力损失严重度仅有的显著性预测因子。

最后,研究人员指出,卡维地洛的长期使用与显著的听力损失相关。该发现促使了使用该药物时所必须的考虑。进一步的随机对照研究,并且在治疗前具有基线听力测定测试和周期性的跟踪调查测试将提供关于卡维地洛对听力的影响更好的评估。

原始出处:

Al-Ghamdi BS, Rohra DK, Abuharb GAI et al. Use of beta blockers is associated with hearing loss. Int J Audiol. 24 Nov 2017.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1306141, encodeId=aa2613061416a, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Fri Dec 08 13:10:00 CST 2017, time=2017-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267482, encodeId=fecf26e482dc, content=学习了.涨知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIKlpu9buib1TxXRibfFuzYXHaLxQgfUpwzYwTMo8551BS40KVZNRDLWmAXSibjfnFm0QggOrCSWElfw/132, createdBy=95aa1617853, createdName=happy1, createdTime=Thu Dec 07 07:43:56 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267452, encodeId=c5dd26e4526d, content=谢谢.先谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Thu Dec 07 07:08:56 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267412, encodeId=e63f26e412d0, content=太吓人了.关注药物副作用., beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/21/9461f3b3c9f14e1d844256cdd08f2cf3.jpg, createdBy=a30f1426910, createdName=swfzhanggui, createdTime=Thu Dec 07 05:34:18 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267383, encodeId=ead726e383e9, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Wed Dec 06 23:32:30 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267347, encodeId=45c226e347ba, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Dec 06 22:26:39 CST 2017, time=2017-12-06, status=1, ipAttribution=)]
    2017-12-08 ysjykql
  2. [GetPortalCommentsPageByObjectIdResponse(id=1306141, encodeId=aa2613061416a, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Fri Dec 08 13:10:00 CST 2017, time=2017-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267482, encodeId=fecf26e482dc, content=学习了.涨知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIKlpu9buib1TxXRibfFuzYXHaLxQgfUpwzYwTMo8551BS40KVZNRDLWmAXSibjfnFm0QggOrCSWElfw/132, createdBy=95aa1617853, createdName=happy1, createdTime=Thu Dec 07 07:43:56 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267452, encodeId=c5dd26e4526d, content=谢谢.先谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Thu Dec 07 07:08:56 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267412, encodeId=e63f26e412d0, content=太吓人了.关注药物副作用., beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/21/9461f3b3c9f14e1d844256cdd08f2cf3.jpg, createdBy=a30f1426910, createdName=swfzhanggui, createdTime=Thu Dec 07 05:34:18 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267383, encodeId=ead726e383e9, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Wed Dec 06 23:32:30 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267347, encodeId=45c226e347ba, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Dec 06 22:26:39 CST 2017, time=2017-12-06, status=1, ipAttribution=)]
    2017-12-07 happy1

    学习了.涨知识了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1306141, encodeId=aa2613061416a, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Fri Dec 08 13:10:00 CST 2017, time=2017-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267482, encodeId=fecf26e482dc, content=学习了.涨知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIKlpu9buib1TxXRibfFuzYXHaLxQgfUpwzYwTMo8551BS40KVZNRDLWmAXSibjfnFm0QggOrCSWElfw/132, createdBy=95aa1617853, createdName=happy1, createdTime=Thu Dec 07 07:43:56 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267452, encodeId=c5dd26e4526d, content=谢谢.先谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Thu Dec 07 07:08:56 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267412, encodeId=e63f26e412d0, content=太吓人了.关注药物副作用., beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/21/9461f3b3c9f14e1d844256cdd08f2cf3.jpg, createdBy=a30f1426910, createdName=swfzhanggui, createdTime=Thu Dec 07 05:34:18 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267383, encodeId=ead726e383e9, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Wed Dec 06 23:32:30 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267347, encodeId=45c226e347ba, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Dec 06 22:26:39 CST 2017, time=2017-12-06, status=1, ipAttribution=)]
    2017-12-07 执着追梦

    谢谢.先谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1306141, encodeId=aa2613061416a, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Fri Dec 08 13:10:00 CST 2017, time=2017-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267482, encodeId=fecf26e482dc, content=学习了.涨知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIKlpu9buib1TxXRibfFuzYXHaLxQgfUpwzYwTMo8551BS40KVZNRDLWmAXSibjfnFm0QggOrCSWElfw/132, createdBy=95aa1617853, createdName=happy1, createdTime=Thu Dec 07 07:43:56 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267452, encodeId=c5dd26e4526d, content=谢谢.先谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Thu Dec 07 07:08:56 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267412, encodeId=e63f26e412d0, content=太吓人了.关注药物副作用., beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/21/9461f3b3c9f14e1d844256cdd08f2cf3.jpg, createdBy=a30f1426910, createdName=swfzhanggui, createdTime=Thu Dec 07 05:34:18 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267383, encodeId=ead726e383e9, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Wed Dec 06 23:32:30 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267347, encodeId=45c226e347ba, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Dec 06 22:26:39 CST 2017, time=2017-12-06, status=1, ipAttribution=)]
    2017-12-07 swfzhanggui

    太吓人了.关注药物副作用.

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1306141, encodeId=aa2613061416a, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Fri Dec 08 13:10:00 CST 2017, time=2017-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267482, encodeId=fecf26e482dc, content=学习了.涨知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIKlpu9buib1TxXRibfFuzYXHaLxQgfUpwzYwTMo8551BS40KVZNRDLWmAXSibjfnFm0QggOrCSWElfw/132, createdBy=95aa1617853, createdName=happy1, createdTime=Thu Dec 07 07:43:56 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267452, encodeId=c5dd26e4526d, content=谢谢.先谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Thu Dec 07 07:08:56 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267412, encodeId=e63f26e412d0, content=太吓人了.关注药物副作用., beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/21/9461f3b3c9f14e1d844256cdd08f2cf3.jpg, createdBy=a30f1426910, createdName=swfzhanggui, createdTime=Thu Dec 07 05:34:18 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267383, encodeId=ead726e383e9, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Wed Dec 06 23:32:30 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267347, encodeId=45c226e347ba, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Dec 06 22:26:39 CST 2017, time=2017-12-06, status=1, ipAttribution=)]
    2017-12-06 清风拂面

    谢谢分享.学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1306141, encodeId=aa2613061416a, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Fri Dec 08 13:10:00 CST 2017, time=2017-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267482, encodeId=fecf26e482dc, content=学习了.涨知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIKlpu9buib1TxXRibfFuzYXHaLxQgfUpwzYwTMo8551BS40KVZNRDLWmAXSibjfnFm0QggOrCSWElfw/132, createdBy=95aa1617853, createdName=happy1, createdTime=Thu Dec 07 07:43:56 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267452, encodeId=c5dd26e4526d, content=谢谢.先谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Thu Dec 07 07:08:56 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267412, encodeId=e63f26e412d0, content=太吓人了.关注药物副作用., beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/21/9461f3b3c9f14e1d844256cdd08f2cf3.jpg, createdBy=a30f1426910, createdName=swfzhanggui, createdTime=Thu Dec 07 05:34:18 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267383, encodeId=ead726e383e9, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Wed Dec 06 23:32:30 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267347, encodeId=45c226e347ba, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Dec 06 22:26:39 CST 2017, time=2017-12-06, status=1, ipAttribution=)]
    2017-12-06 1ddf0692m34(暂无匿称)

    学习了.涨知识

    0

相关资讯

PLoS One:在法布里病病人中,心脏和肾脏功能障碍与晚期听力损失相关

法布里疾病(FD)是一种X染色体连锁的隐性遗传性溶酶体储存障碍,并且能够导致糖鞘脂(Gb3)在肾脏和心脏组织中的积累以及在中央和周围神经系统中的积累。除了明显的肾脏和心脏器官的参与之外,耳蜗症状比如高频听力损失和耳鸣经常能够出现,并且到目前为止没有全面的可利用资料来阐释这种现象。最近,有研究人员在患有FD的病人中,依据心脏和肾脏功能调查了听力损失的情况。研究人员在2012年和2016年之间招募了6

J Speech Lang Hear Res:使用助听器或耳蜗移植时,患有语前聋年轻人对“重点关注“的识别和理解的分析

在题目中强调词""重点关注(NF)"就是指关于说话的人的所表达目的的相关信息,因此在处理口语和社会交际过程中是非常重要的。对于那些患有重度到永久性语前聋的病人对NF的理解能力很少有人研究。最近,有研究人员评估并比较了患有语前聋的年轻成年人与那些具有正常听力(NH)年轻成年人对NF的识别和理解。研究包括了使用助听器的年轻成年人(HA;n=10)、耳蜗移植年轻成年人(CI;n=12)和具有正常听力的年

Nat Commun:化疗后,顺铂在耳蜗内具有不确定的残留

顺铂化疗可以在40%-80%的治疗的病人中引起永久性听力损失。然而,耳蜗是否对顺铂具有特殊的敏感性或者接触到了更高水平的顺铂药物仍旧不清楚。最近,有研究人员利用电感藕合等离子体质谱(ICP-MS)技术检测了小鼠和人类耳蜗中顺铂药物动力学。研究发现,在大多数器官中,顺铂在注射后1个小时内就能检测到,并且在随后的几天或者几周内消除。与之相反,在小鼠和人类处理中,耳蜗能够残留顺铂长达数个月甚至数年。研究

Ear Nose Throat J:感官性听力损失和慢性耳漏之间的关系分析

许多研究都尝试在儿童和成年人中将慢性耳漏和感官听力损失联系起来,但是总有相矛盾的结果。听力损失造成的原因可能是细菌参与产生的毒性、炎症性细胞因子的影响或者是有耳毒性的抗生素的持续使用。研究人员的所有的研究都评估比较了受影响的耳朵和正常的对侧耳朵。另外,在圣保罗市圣保罗学校医学院耳鼻喉门诊的耳外科学数字化档案中,研究人员评估了患有慢性耳漏病人的耳朵,并且与正常的对侧耳朵进行了比较。耳漏的耳朵同样也与

Clin Otolaryngol:噪音诱导的听力损失分析

最近,有研究人员在一个代表性研究中,对87名工业工人的噪音诱导的听力损失的评估的方法进行了调查。根据健康和安全部门(HSE)的噪音诱导的听力损失(NIHL)监督与用于评估噪音诱导的听力损失的法医鉴定标准是不同的。研究人员在该研究中比较了这两种系统,并且提出了一种新的方法,从而简化法医鉴定标准并且应用于确定噪音诱导的听力损失中。研究人员对来自一个地点的87没那个工业工人的匿名听力敏度图进行了分析,分

Eur Arch Otorhinolaryngol:贝尔氏麻痹病人听力损失流行度和特性分析

最近,有研究人员进行了旨在评估患有贝尔氏麻痹(BP)病人听力损失的发生率,并且鉴定和分析了其临床特性。研究包括了那些患有BP且经过听觉测试的病人,地点在研究人员所在的机构。研究人员对麻痹侧的同侧耳朵和对侧耳朵的骨听力水平差异进行了分析,频率包括了250、500、1000、2000、4000和8000 Hz。在至少1种频率情况下,那些两耳差异超过5dB的参与者被认为是患有同侧单边感官性听力损失(uS

Baidu
map
Baidu
map
Baidu
map